WeedStreet420
  • Newsletter
  • Colors
    Light Theme Dark Theme
    Screen options
    Full Screen Mode Boxed Layout Mode
    • Watch List
      • Daily Top Gainers
      • Daily Top Losers
      • 52-Weeks Highs
      • Most Volume
    • Psychedelics Companies List
    • TOP PICKS
    • Press Releases
    • News
      • All News
      • Shroom Stocks News
      • Science & Studies
      • Legislation News
    • Heat Map
    • Calendar
  • Watch List
    • Daily Top Gainers
    • Daily Top Losers
    • 52-Weeks Highs
    • Most Volume
  • Psychedelics Companies List
  • TOP PICKS
  • Press Releases
  • News
    • All News
    • Shroom Stocks News
    • Science & Studies
    • Legislation News
  • Heat Map
  • Calendar
WeedStreet420

SUBSCRIBE NOW

Join our subscribers!

By subscribing, you agree to our Terms and Conditions
We don't spam and we promise to never share your information.

493 views3 min read

PSYC Expanding Their Global Reach To Showcase Psychedelic Industry Leaders and Pioneers

Global Trac SolutionsJune 10, 2020 -

SAN DIEGO, CA, June 10, 2020 — Global Trac Solutions, Inc. (OTCPink: PSYC) (“Global” “PSYC” or the “Company”) is pleased to announce that in an effort to provide its growing base of Psychedelic Spotlight newsletter subscribers with exclusive content surrounding the ongoing boom within the medicinal psychedelics space, the Company plans to launch a series of exclusive interviews with some of today’s industry-leading advocates, pioneers, and trail blazers.

“Immersing ourselves within this industry and becoming a true ally for those who are currently advocating for a variety of psychedelic-related treatments is a very important objective of ours,” said Vanessa Luna Global Trac Solutions, Inc. CEO. “There are a multitude of individuals across the globe who are working incredibly hard to shed an important and valuable light on the benefits of incorporating certain psychedelics such as psilocybin into therapeutic treatments for those suffering from depression, anxiety, and addiction. It is our goal to leverage the platform we are creating with Psychedelic Spotlight and utilize it as a sounding board to help amplify the relevant initiatives, perspectives, stories, and insights from the individuals who are dedicated to highlighting the many reasons why psychedelics should be regarded as the breakthrough therapy it truly is.”


  Subscribe to news from
Global Trac Solutions

Be the first to know when breaking news are released.



In the coming weeks and months, the Company intends to reach out and speak with a variety of individuals within the growing psychedelic community in an attempt to share their unique thoughts and perspectives related to the benefits of specific psychedelics as a therapeutic treatment for certain mental disorders and will incorporate these interactions into the content it shares through its monthly Psychedelic Spotlight newsletter and website (www.psychedelicspotlight.com).

About Global Trac Solutions, Inc. (OTC Pink:PSYC)

Global Trac Solutions is a diversified holding company dedicated to identifying new and emerging industries. By utilizing our years of business development expertise our diverse team of innovators continuously leverages our experience to effectively execute go-to-market strategies in order to position ourselves for rapid growth through the creation of an evolving business foundation to enhance profitability potential.

Since 2017, PSYC has been a pioneer in the emerging software and payment processing sector of the cannabis industry and has established itself as a trusted resource for businesses operating within the industry. Today, PSYC through its network of partners and affiliates, continues to connect businesses throughout the cannabis industry with critical solutions and services ranging from payment processing technology, cutting-edge software, and ancillary services vital to compliant and effective business operations.

Most recently, PSYC has expressed its intent and commitment to positioning itself at the forefront of the psychedelic revolution and as a resource center for discovering and understanding the latest research and business opportunities surrounding psychedelic inspired medicines. In conjunction with the FDA’s more open-minded approach to psychedelic medicines, and as several major U.S. cities continue to approve the decriminalization of psilocybin, investors are speculating that the psychedelic boom could be bigger than that of cannabis. PSYC is your source for current investment related news specific to psychedelic medicines and cutting-edge research improving overall health, moving this sector into the mainstream.

We believe in a forward-thinking approach that embraces groundbreaking new technology and innovations and through the vision of business development we intend to continue to evolve into these unchartered territories as the industry leaders of the future. We truly are the right TRAC to follow.

Forward-Looking Statements Disclaimer:

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainty and other factors that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of all filings of the Company that are disclosed on the OTC Markets.com website.

Corporate Contact:

Global Trac Solutions, Inc. (PSYC)
www.globaltracsolutions.com
(619) 925-3202
[email protected]

  • Share on Twitter
  • Facebook
  • Reddit
  • LinkedIn

Global Trac Solutions Inc.PSYC





More news from Global Trac Solutions

  • PSYC Attracts Hundreds of Subscribers For Their Monthly Newsletter Launch in June

    Global Trac SolutionsJune 3, 2020 -
  • PSYC Launches Psychedelic Spotlight Website

    Global Trac SolutionsMay 28, 2020 -
  • PSYC Begins Assembling Team for Original Content Creation

    Global Trac SolutionsMay 20, 2020 -
  • PSYC Publishes 2019 Audited Financials, Paves the Way for Form 10 Filing

    Global Trac SolutionsMay 18, 2020 -
  • PSYC Receives Additional Capital at 10x to Finalize 2019 Audit and File Registration Statement

    Global Trac SolutionsMay 12, 2020 -
  • PSYC Gaining Traction on Subscribership for the Launch of Psychedelic Spotlight

    Global Trac SolutionsMay 7, 2020 -

View Watch List (65 companies)

POPULAR

Field Trip Health & Wellness Announces Posting on the OTC Market

1352 Views

Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch

1322 Views

PharmAla Named Exclusive MDMA Supplier to Revive Therapeutics

841 Views

Silo Pharma Announces Expansion of Intellectual Property Portfolio

75 Views

Algernon Pharmaceuticals subsidiary Algernon NeuroScience doses first patient in stroke study

41 Views

Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development

13 Views

Halucenex Life Sciences Inc. targets Australian market following landmark TGA decision

6 Views

Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements

5 Views

RECENT

Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements

0 Views

Halucenex Life Sciences Inc. targets Australian market following landmark TGA decision

0 Views

PharmAla Named Exclusive MDMA Supplier to Revive Therapeutics

0 Views

Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development

0 Views

Algernon Pharmaceuticals subsidiary Algernon NeuroScience doses first patient in stroke study

0 Views

Field Trip Health & Wellness Announces Posting on the OTC Market

0 Views

Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch

0 Views

Silo Pharma Announces Expansion of Intellectual Property Portfolio

0 Views

Numinus Receives Clinical Trial Application Approval from Health Canada for Experiential Psychedelic-Assisted Therapy Training using Psilocybe Cubensis Tea

0 Views

Silo Pharma Announces Stock Repurchase Program

0 Views





Make smarter investment strategies
with in-depth news reports

Join our subscribers!

By subscribing, you agree to our Terms and Conditions
We don't spam and we promise to never share your information.

Risk Warning
Privacy Policy
Methodology
Disclaimer
Contact Us
Advertising
© 2023 Shroom Investor 🍄 is a subsidiary of Upside Makers inc.   By using this website, you agree to our Terms of Use